154 related articles for article (PubMed ID: 34261467)
1. Molecular mechanism study of HGF/c-MET pathway activation and immune regulation for a tumor diagnosis model.
Shen Z; Xue W; Zheng Y; Geng Q; Wang L; Fan Z; Wang W; Yue Y; Zhai Y; Li L; Zhao J
Cancer Cell Int; 2021 Jul; 21(1):374. PubMed ID: 34261467
[TBL] [Abstract][Full Text] [Related]
2. Role of HGF/MET axis in resistance of lung cancer to contemporary management.
Raghav KP; Gonzalez-Angulo AM; Blumenschein GR
Transl Lung Cancer Res; 2012 Sep; 1(3):179-93. PubMed ID: 25806180
[TBL] [Abstract][Full Text] [Related]
3. Roles of the HGF/Met signaling in head and neck squamous cell carcinoma: Focus on tumor immunity (Review).
Liu D; Zhong M; Zhan D; Zhang Y; Liu S
Oncol Rep; 2020 Dec; 44(6):2337-2344. PubMed ID: 33125120
[TBL] [Abstract][Full Text] [Related]
4. The potential therapeutic and prognostic impacts of the c-MET/HGF signaling pathway in colorectal cancer.
Parizadeh SM; Jafarzadeh-Esfehani R; Fazilat-Panah D; Hassanian SM; Shahidsales S; Khazaei M; Parizadeh SMR; Ghayour-Mobarhan M; Ferns GA; Avan A
IUBMB Life; 2019 Jul; 71(7):802-811. PubMed ID: 31116909
[TBL] [Abstract][Full Text] [Related]
5. The Role of HGF/MET Signaling in Metastatic Uveal Melanoma.
Tanaka R; Terai M; Londin E; Sato T
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771620
[TBL] [Abstract][Full Text] [Related]
6. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer.
Toiyama Y; Yasuda H; Saigusa S; Matushita K; Fujikawa H; Tanaka K; Mohri Y; Inoue Y; Goel A; Kusunoki M
Int J Cancer; 2012 Jun; 130(12):2912-21. PubMed ID: 21796631
[TBL] [Abstract][Full Text] [Related]
7. Status of Agents Targeting the HGF/c-Met Axis in Lung Cancer.
Miranda O; Farooqui M; Siegfried JM
Cancers (Basel); 2018 Aug; 10(9):. PubMed ID: 30134579
[TBL] [Abstract][Full Text] [Related]
8. Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome.
Kammula US; Kuntz EJ; Francone TD; Zeng Z; Shia J; Landmann RG; Paty PB; Weiser MR
Cancer Lett; 2007 Apr; 248(2):219-28. PubMed ID: 16945480
[TBL] [Abstract][Full Text] [Related]
9. HGF and TGFβ1 differently influenced Wwox regulatory function on Twist program for mesenchymal-epithelial transition in bone metastatic versus parental breast carcinoma cells.
Bendinelli P; Maroni P; Matteucci E; Desiderio MA
Mol Cancer; 2015 Jun; 14():112. PubMed ID: 26041563
[TBL] [Abstract][Full Text] [Related]
10. Osthole suppresses hepatocyte growth factor (HGF)-induced epithelial-mesenchymal transition via repression of the c-Met/Akt/mTOR pathway in human breast cancer cells.
Hung CM; Kuo DH; Chou CH; Su YC; Ho CT; Way TD
J Agric Food Chem; 2011 Sep; 59(17):9683-90. PubMed ID: 21806057
[TBL] [Abstract][Full Text] [Related]
11. HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers.
Moosavi F; Giovannetti E; Saso L; Firuzi O
Crit Rev Clin Lab Sci; 2019 Dec; 56(8):533-566. PubMed ID: 31512514
[TBL] [Abstract][Full Text] [Related]
12. Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment.
Rothenberger NJ; Stabile LP
Cancers (Basel); 2017 Apr; 9(4):. PubMed ID: 28441771
[TBL] [Abstract][Full Text] [Related]
13. SOX9 in prostate cancer is upregulated by cancer-associated fibroblasts to promote tumor progression through HGF/c-Met-FRA1 signaling.
Qin H; Yang Y; Jiang B; Pan C; Chen W; Diao W; Ding M; Cao W; Zhang Z; Chen M; Gao J; Zhao X; Qiu X; Guo H
FEBS J; 2021 Sep; 288(18):5406-5429. PubMed ID: 33705609
[TBL] [Abstract][Full Text] [Related]
14. Structural and Functional Insight Into the Glycosylation Impact Upon the HGF/c-Met Signaling Pathway.
Hu X; Tang F; Liu P; Zhong T; Yuan F; He Q; von Itzstein M; Li H; Weng L; Yu X
Front Cell Dev Biol; 2020; 8():490. PubMed ID: 32626713
[TBL] [Abstract][Full Text] [Related]
15. Hepatocyte growth factor/MET in cancer progression and biomarker discovery.
Matsumoto K; Umitsu M; De Silva DM; Roy A; Bottaro DP
Cancer Sci; 2017 Mar; 108(3):296-307. PubMed ID: 28064454
[TBL] [Abstract][Full Text] [Related]
16. Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment.
Kwon Y; Smith BD; Zhou Y; Kaufman MD; Godwin AK
Oncogene; 2015 Jan; 34(2):144-53. PubMed ID: 24362531
[TBL] [Abstract][Full Text] [Related]
17. HGF/c-MET targeted therapeutics: novel strategies for cancer medicine.
Yap TA; Sandhu SK; Alam SM; de Bono JS
Curr Drug Targets; 2011 Dec; 12(14):2045-58. PubMed ID: 21777195
[TBL] [Abstract][Full Text] [Related]
18. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy.
Li Y; Lal B; Kwon S; Fan X; Saldanha U; Reznik TE; Kuchner EB; Eberhart C; Laterra J; Abounader R
Cancer Res; 2005 Oct; 65(20):9355-62. PubMed ID: 16230398
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling.
Owusu BY; Bansal N; Venukadasula PK; Ross LJ; Messick TE; Goel S; Galemmo RA; Klampfer L
Oncotarget; 2016 May; 7(20):29492-506. PubMed ID: 27121052
[TBL] [Abstract][Full Text] [Related]
20. Cyr61 mediates hepatocyte growth factor-dependent tumor cell growth, migration, and Akt activation.
Goodwin CR; Lal B; Zhou X; Ho S; Xia S; Taeger A; Murray J; Laterra J
Cancer Res; 2010 Apr; 70(7):2932-41. PubMed ID: 20233866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]